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Abstract
Eliciting broadly neutralizing antibodies (bnAb) in cervicovaginal mucus (CVM) represents a promising ‘‘first line of defense’’
strategy to reduce vaginal HIV transmission. However, it remains unclear what levels of bnAb must be present in CVM to
effectively reduce infection. We approached this complex question by modeling the dynamic tally of bnAb coverage on HIV.
This analysis introduces a critical, timescale-dependent competition: to protect, bnAb must accumulate at sufficient
stoichiometry to neutralize HIV faster than virions penetrate CVM and reach target cells. We developed a model that
incorporates concentrations and diffusivities of HIV and bnAb in semen and CVM, kinetic rates for binding (kon) and
unbinding (koff) of select bnAb, and physiologically relevant thicknesses of CVM and semen layers. Comprehensive model
simulations lead to robust conclusions about neutralization kinetics in CVM. First, due to the limited time virions in semen
need to penetrate CVM, substantially greater bnAb concentrations than in vitro estimates must be present in CVM to
neutralize HIV. Second, the model predicts that bnAb with more rapid kon, almost independent of koff, should offer greater
neutralization potency in vivo. These findings suggest the fastest arriving virions at target cells present the greatest
likelihood of infection. It also implies the marked improvements in in vitro neutralization potency of many recently
discovered bnAb may not translate to comparable reduction in the bnAb dose needed to confer protection against initial
vaginal infections. Our modeling framework offers a valuable tool to gaining quantitative insights into the dynamics of
mucosal immunity against HIV and other infectious diseases.
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Introduction
During vaginal transmission of HIV-1, virions in semen must
traverse the thin layer of cervicovaginal mucus (CVM) coating the
vaginal epithelium before they can encounter and potentially
infect target cells (lymphocytes, macrophages, dendritic cells and
Langerhans cells). Due to the presence of substantial quantities of
secreted and transudated antibodies (Ab) [1,2], CVM possesses
both diffusional and immunological barrier properties against
sexually transmitted viruses. In women with healthy vaginal
microflora, lactobacilli secrete substantial levels of lactic acid,
producing an acidic (pH ,3.5–4) environment that inactivates
leukocytes within minutes [3]. Thus, few immune cells capable of
opsonization and antibody-dependent cell-mediated cytotoxicity
(ADCC) are actually present in healthy CVM secretions, which
also exhibit limited complement activity [4–6]. Neutralization, a
process in which secreted or topically-applied Ab engage the
gp120/gp41 trimeric glycoproteins (Env) on HIV at sufficient
stoichiometry to preclude their attachment to target cells, is thus
generally thought to be a critical component of sterilizing
immunity against initial HIV infections in the vagina [7]. Effective
neutralization in the vaginal lumen that directly reduces the rates
of acquiring initial infections, rather than attempting to clear
infections, may be especially important since HIV infections
remain difficult to cure once established.
In response to the tremendous genetic diversity of HIV, a series
of monoclonal Ab capable of broadly neutralizing diverse strains of
HIV across different clades (abbreviated here as bnAb) have been
recently discovered that not only neutralize a much greater
diversity of HIV strains than previously, but also extend the in vitro
geometric mean IC50 (the concentration necessary to reduce
infectivity by 50%) into ng/mL potencies [8–10]. Because of the
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high affinity of typical Ab-antigen binding, it is generally assumed
that these potent bnAb rapidly bind to and neutralize HIV.
However, viruses that transmit at mucosal surfaces have generally
evolved to readily penetrate mucus [11]. Indeed, HIV virions
(diameter ,100 nm) exhibit rapid diffusion in pH-neutralized
CVM, enabling their rapid penetration across physiologically thick
mucus layers in tens of minutes [12]. Thus, there is a very limited
time window during which bnAb must accumulate on HIV at or
above the neutralizing threshold before the virions can successfully
diffuse across CVM and reach target cells. This challenge is not
readily captured by most in vitro studies, where the majority of
assays evaluate protection by incubating Ab with HIV for defined
durations (e.g., 60 mins, some extending to overnight) prior to
assaying infection of target cells over a 48–72 hr period. This
procedure likely ensures greater Ab coverage on HIV prior to their
exposure to target cells in vitro. It remains unclear whether bnAb in
CVM at in vitro IC50 or IC80 concentrations can achieve
neutralization potencies comparable to those measured in vitro
within the limited time window before virions successfully
penetrate mucus and infect target cells, or if not, how much more
bnAb may be needed to achieve such sterilizing immunity in the
human vagina.
To address these competing processes and their respective
timescales, as well as gain insight into the dynamics of vaginal HIV
infection, we developed a mathematical model that captures the
competition between bnAb accumulation on the fusion-competent
envelope glycoprotein of HIV and HIV penetration of CVM from
semen in the lumen. Using previous measurements of HIV
mobility and Ab diffusivities in human genital secretions, estimates
of CVM thickness, and binding affinities for different bnAb based
on surface plasmon resonance (SPR) measurements, we model the
minimum Ab levels in CVM necessary to achieve 50% and 80%
coverage of the HIV Env spikes before HIV virions can reach the
vaginal epithelium. We also present theoretical binding affinities
for bnAb that may enable protective immunity against HIV in the
human vagina.
Materials and Methods
Defining model parameters capturing vaginal
transmission of cell-free HIV
Our mathematical model describes the dynamics of male-to-
female HIV transmission, beginning the instant semen is
ejaculated into the vaginal lumen and tracking HIV virions until
they reach the vaginal epithelium (see Figure 1 for schematic;
Table 1 lists the various input parameters). Once virions reach the
epithelial lumen, virions must still access target cells in the
epithelium, and intact stratified vaginal epithelia has long been
believed to serve as a mechanical barrier excluding virus access.
Nevertheless, HIV virions have been observed to quickly penetrate
the superficial layers of the stratified epithelium in human cervical
explants and the female rhesus macaque genital tract, thereby
gaining access to superficial Langerhans cells and CD4 T cells
[13,14]. The timescale required for successful cellular penetration
of HIV may be further reduced by any pre-existing micro or
macro lesions in the epithelium as well as abrasions upon coital
stirring [15,16]. Thus, in the absence of an established mathe-
matical model that can accurately recapitulate HIV penetration of
the squamous epithelium, we chose virion passage through the
CVM layer as the time scale to evaluate Ab coverage on virions.
Similar assumptions were previously made by the Katz group to
model the efficacy of microbicides against HIV [17,18].
The vaginal epithelium is highly folded into collapsed ‘‘rugae’’
coated with a layer of viscoelastic and adhesive cervicovaginal
mucus (CVM) gel (Figure 1, top left panel). During coitus, the
epithelium becomes stretched and exposed. We thus model the
vaginal epithelial surface as the inner surface of a simple cylinder
coated with a roughly d = 50 mm thick CVM layer containing
different concentrations of elicited or topically dosed bnAb. The
thickness of the CVM coating is estimated based on total volumes
of mucus that can be collected in the absence of coital stimulation,
and assumed to be constant and uniform (see footnote (ii), Table 1;
Figure 1). Following ejaculation, seminal fluid is assumed to evenly
overlay the CVM layer with a thickness of ,200 mm, with virions
uniformly dispersed within the seminal secretions at a density of
Figure 1. Schematic of our model for HIV diffusion from seminal secretions across antibody-laden cervicovaginal mucus (CVM)
layer to underlying vaginal epithelium. To reduce infection, we assume Ab must bind to HIV before virions successfully reach the vaginal
epithelium.
doi:10.1371/journal.pone.0100598.g001
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2.86105 virions/mL (Table 1). Due to rapid diffusivity of protons,
semen-mediated neutralization of CVM is assumed to occur
instantaneously; we have previously found HIV virions readily
diffuse across pH-neutralized CVM, but not acidic native
secretions from women with healthy, lactobaccili-dominated
vaginal flora [12]. Virions, with N = 1467 Env trimers (range
4–35) [19], are assumed to maintain native infectivity for the entire
duration of the model; thermal degradation based on gp120
shedding (T1/2 , 30 hrs) and thermal degradation from RNA
polymerase decay (T1/2 , 40 hrs) were not incorporated because
of the substantial difference in the rate of these processes from the
time scale of interest [20]. Because the kinetics of HIV virions
penetrating the vaginal epithelium and reaching target cells in the
submucosa remain poorly understood, the mobility and number of
bound bnAb on each virion is simulated until the virion reaches
the vaginal epithelium, or at the end of 2 hrs, whichever comes
first. The affinities for different bnAb to purified gp120 as
measured by SPR, as well as the corresponding IC50 and IC80
against the HIV strains from which the purified gp120 are derived,
are listed in Table 2. It is important to note that there are
substantial variations in the approaches used to measure binding
affinities, which range from the use of monomeric gp120 binding
to immobilized IgG, to Fab binding to directly immobilized
monovalent gp120, to IgG binding to directly immobilized,
uncleaved trimers but fitted with a model for monovalent
interaction, and finally the binding of uncleaved trimers to
captured Fabs, a potentially trivalent interaction, fitted with a
monovalent model. None of these approaches would yield the
perfect kon/koff values for the model here, but in the absence of
other reported binding affinity values, we use the currently
available literature values as a first estimate. We subsequently
included a phase diagram that explores in detail how variations in
kon/koff might impact our conclusions.
Modeling simultaneous diffusion of HIV-1 and Env-
binding Ab
We model viruses and bnAb undergoing Brownian motion in
CVM/semen mixture, assuming coital stirring motion does not
influence the movement of virions into the epithelial layer, due to
the viscoelastic nature of CVM. When mucus is sheared between
two surfaces, adhesive contacts and entanglements between mucin
fibers are drawn apart and a slippage plane forms parallel to the
two surfaces, which is reflected by the shear-thinning rheological
profile of mucus [4,21]. Thus, while the viscous drag between the
surfaces drops considerably, enabling mucus to function as an
effective lubricant, the gel layers adhering to both surfaces remain
unstirred even in the presence of vigorous shearing actions. Hence
viruses in semen are unlikely to get easily stirred into the mucus
layer adhering to the vaginal epithelium.
We model the dynamics of virions and bnAb in two ways: a
hybrid stochastic/deterministic system in which we simulate
individual virion paths each with unique bnAb binding and
unbinding timelines, and a fully deterministic system in which the
binding and unbinding rates are expressed in terms of virion and
bnAb concentrations. Deterministic models of the virion-bnAb
Table 1. Parameters and values incorporated into the model.
Category Parameter Symbol Value Reference(s)
HIV-1
Radius rHIV 50 nm [19]
Diffusivity in semen Assume same as in CVM
Diffusivity in CVM Dv 1.27 mm
2/s i [12]
Viral load in semen 8.46105 copies/ejaculate ii [47], [48]
Number of Env trimer spikes N* 14+/27 (s.d.) [19]
bnAb (IgG)
Diffusivity in semen Assume same as in CVM
Diffusivity in CVM DAb 40 mm
2/s [11,32]
bnAb conc in CVM Variable
bnAb – Env affinity kon, koff Variable; see Table 2
Vagina
Surface area of lumen SAvagina 145 cm
2 iii [49,50]
Volume of luminal CVM VCVM ,750 uL [51,52]
Thickness of CVM Layer HCVM
iv 50 mm v
Volume of semen VSemen ,3.0 mL [48]
Thickness of semen layer HSemen
iv 200 mm v
iGeometrically averaged Deff for HIV was previously measured to be 0.25 mm
2/s, but with substantial fraction of viruses exhibiting more rapid mobility. For the current
analysis, we used 1.27 mm2/s, which represented the top 25th percentile of virus mobility; this is in reasonable agreement with a more recent study of HIV diffusion in
genital secretions [53].
iiEstimated based on a median semen volume of 3.0 mL [48], and 2.86105 HIV-1 RNA copies/mL, which represents the upper limit of HIV-1 RNA copies/mL in seminal
plasma from [47]. This is in reasonable agreement with another report by Chakraboty el al., which estimated 56105 HIV-1 RNA copies/ejaculate, with a maximum of
about 26107 HIV-1 RNA copies/ejaculate [54].
iiiThe mean surface area of the vagina in the native state was previously estimated to be ,90 cm2 by injection of vinyl polysiloxane casts vaginally. Alternatively, surface
area of vaginal lumen may also be inferred by the surface area of erect penis (average ,200 cm2) assuming complete insertion into the vagina. We took the average
from the two approaches.
ivIn the Materials and Methods section, HCVM is referred to as d and HCVM+HSemen = L.
vHCVM estimated by VCVM/SAvagina; HSemen estimated by VSemen/SAvagina.
doi:10.1371/journal.pone.0100598.t001
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binding kinetics have been previously described by Geonnotti and
Katz [18] and more recently by Magnus [22]. The model of
Gennotti and Katz also incorporates much of the same biophysical
geometry as presented here, while the model developed by
Magnus et al. [22,23] provides a rich investigation of the
neutralization of virions that results from bnAb binding. When
viral concentrations are low, the dynamics are intrinsically
stochastic. Our stochastic/deterministic hybrid model yields more
detailed information concerning the distribution of possible events
and reveals the important role played by constraints to the length
and time scales appropriate for in vivo dynamics.
In the stochastic/deterministic hybrid model, we describe the







where Z tð Þ denotes the distance from the epithelial layer of a
virion at time t, W tð Þ denotes standard Brownian motion, and
DHIV is the viral diffusivity. This diffusion coefficient was assumed
to be constant and independent of the evolving number of bound
bnAb; the increase in hydrodynamic diameter of Ab-virus
complex, even when the virion is completely saturated with Ab,
is unlikely to be more than 5–10 nm on a 100 nm virion, and thus
assumed to be negligible. At the time of ejaculation, virions are
assumed to be uniformly distributed throughout the seminal fluid
layer, Z t~0ð Þ*Unif d,L½ ð Þ, where L is the distance of the
semen-air interface from the epithelium, d is thickness of the CVM
layer, with d and L estimated as 50 mm and 250 mm, respectively
(see Figure 1). The boundary at z~L (i.e., the semen-air interface)
is considered to be reflecting, while the boundary between the
mucus and the epithelial layer z~0ð Þ is absorbing.
There are severe computational limitations to direct simulation
of the diffusion of 1012 IgG molecules with specification of their
respective distances from the closest virions. Consequently, we
adopted a continuum model to describe the average local
concentration of bnAb molecules available to bind HIV virions,
an approach used by the Katz group to model the dynamics of
microbicide protection against HIV [17,18]. We assume that
bnAb are uniformly distributed throughout the CVM layer
(0ƒzƒd) at the time of ejaculation (t~0). The diffusion of bnAb
into the seminal fluid layer is described by the diffusion equation






where u z,tð Þ is the local concentration of antibodies, with initial
condition u z,t~0ð Þ~u0,z[ 0,d½  and reflecting boundary condi-
tions at both z~0 (mucus-epithelia interface) and z~L (air-semen
interface).
Kinetics of Ab accumulation on HIV-1
The dynamics of bnAb accumulation on HIV virions depend on
(i) bnAb binding affinity to the Env spike (which incorporates the
‘‘on rate’’ kon for binding and ‘‘off rate’’ koff for unbinding), (ii) the
local bnAb concentration surrounding the virions (which deter-
mines the encounter rate), and (iii) the number of available, bnAb-
free Env spikes on the virion. To formulate the equations
describing the reaction kinetics (see also [18,22]), we introduce
the notation Abð ÞnZ tð Þ to indicate an HIV virion with n bound
bnAb that is located at distance Z from the epithelial layer at time
t. To mimic the observed distribution of 1467 Env trimers (range
4–35) [19], we select the simulated number of Env trimers N from
a Negative Binomial distribution with parameters chosen to yield
the observed mean and standard deviation. With the exception of
bnAb with one Fab bound per trimer (e.g., PG9), there are 3N
gp120 epitopes available for bnAb binding per Env, and the
reaction kinetics can be summarized by the following rates for Ab
binding and unbinding between n and nz1 bound bnAb states:
Table 2. Binding kinetics and neutralization potencies of bnAb.
Ab Env strain & type kon [M
21s21] koff [s
21] IC50 [mg/mL] IC80 [mg/mL] Reference(s)
b12* YU2 gp120 4.85e4 1.85e-3 2.2 7.8 [10]
b12 JRFL gp120 7.06e4 4.74e-3 0.022 0.075 [10,55]
b12 JRCSF gp120 1.73e5 4.77e-3 0.096 0.874 [10,56]
2G12 92UG037.8 gp140 8.4e3 6.0e-3 45.24 [57,58]
2G12* HXB2 gp120 1.83e5 1.08e-3 1.01 2.19 [1,59]
VRC01* YU2 gp120 1.43e4 5.56e-5 0.126 0.372 [10]
VRC01 YU2 gp140 1.83e4 8.08e-6 0.12 0.372 [60]
VRC01 92UG037.8 gp140 1.6e4 6.4e-5 0.035 0.130 [1]
VRC03* YU2 gp120 1.33e4 9.74e-4 0.037 0.115 [10]
NIH45-46* YU2 gp140 4.26e4 2.87e-4 0.05 0.08 [60]
PG9 ZM109 gp120 2.95e4 2.85e-3 0.106 2.64 [1]
PG9 C97ZA012 gp140 1.4e4 2.5e-3 8.20 .25 [57]
PG9* 92UG037.8 gp140 1.9e4 1.0e-3 0.04 0.17 [57]
PG16 C97ZA012 gp140 1.6e4 4.2e-3 2.90 .25 [57]
PG16* 92UG037.8 gp140 2.4e4 1.8e-3 ,0.01 0.03 [57]
VRC-CH31 C97ZA012 gp140 9.7e3 1.3e-4 0.18 0.47 [57]
VRC-CH31* 92UG037.8 gp140 8.9e3 4.0e-5 0.04 0.08 [57]
Asterisks indicate kon and IC values that were used in our model to generate Figures 3B, 4 and Figure S2 in File S1.
doi:10.1371/journal.pone.0100598.t002
Neutralization Kinetics of HIV in Genital Mucosa
PLOS ONE | www.plosone.org 4 June 2014 | Volume 9 | Issue 6 | e100598
Abð Þz Abð ÞnZ tð Þ
nz1ð Þkoff
'
(3N{n)konu Z tð Þ,tð Þ
Abð Þnz1Z tð Þ
Mathematically, we treat N tð Þ–a time-dependent stochastic
process for the number n of bnAb bound to a given virion–as a
continuous time random walk (CTRW) on the values 0, . . . ,3Nf g
with Markovian transitions because we assume for simplicity that
the probability of gaining or losing an antibody depends
exclusively on the state of the virion-bnAb system at time t. The
respective probabilities of gaining an antibody, losing an antibody,
or undergoing no change at a location z during an infinitesimal
time increment of size Dt are:
P(N tzDtð Þ{N tð Þ~1jN tð Þ~n)~(3N{n)konu z,tð ÞDtzo Dtð Þ
P(N tzDtð Þ{N tð Þ~{1jN tð Þ~n)~nkoff Dtzo Dtð Þ
P(N tzDtð Þ{N tð Þ~0DN tð Þ~n)
~1{(3N{n)konu z,tð ÞDt{nkoff Dtzo Dtð Þ:
The first equation, for example, asserts that the probability of a
binding event occurring in the small time interval Dt, i.e.,
P N tzDtð Þ{N tð Þ~1ð Þ, conditional on currently being bound
by n bnAb, i.e., N tð Þ~n, is proportional to the local bnAb
concentration u z,tð Þ and the total number of available spikes
(3N{n). The probability of more than one binding event is
higher order in Dt [o Dtð Þ,that is, going to zero faster than Dt in the
limit of small Dt] [24]. Because the number of bnAb is large
compared to the number of virions, even at relatively low
concentration (e.g., 0.01 mg/mL), we ignore local depletion of
unbound bnAb that may occur after a binding event. Because the
reaction rates are time dependent we implemented a Poisson
thinning method [25], which is described in the supplemental text
in File S1.
In order to validate our conclusions from the above probabilistic
discrete event model, we compare results from a continuum model
for both the virus and bnAb populations to binding kinetics
modeled via coupled partial differential equations describing the
local concentrations of virions with each possible number of bound
bnAb. This is valid when both populations are very large. In this
formulation, virus concentration is given as a vector
~v z,tð Þ~ v0 z,tð Þ,v1 z,tð Þ,    ,v3N z,tð Þð Þ
T
, with each component of
the vector indicating the concentration profile of virions bound by
the given number of bnAb. Instead of a Brownian motion
description of individual particle paths, the virus concentration for






, for i~0,1, . . . ,3N. Boundary conditions are
absorbing at z~0 and reflecting at z~L. The Forward Time
Central Space scheme was used to evolve the diffusion equation.
Then the flux for each component at the boundary z~0 is




probabilities for gain, loss, and no change in the time increment Dt
specify transition probabilities in a matrix S tð Þ, depending on the
kinetic rate constants and on the evolving bnAb concentration
u z,tð Þ, which we use to update the bound populations in a first-
order implementation of the form ~v z,tzDtð Þ~S~v z,tð Þ. The
continuum model agrees extremely well with the Brownian/
continuum model for both virus and bnAb populations, and is
used to generate Figures 2–5.
It should be noted that a continuum model for bnAb population
fails to rigorously account for the propensity for a given bnAb to
immediately rebind to a virion after unbinding, either at the same
or neighboring gp120 site. To compensate for the resulting
overestimate in effective unbinding rates, which is reflected in
Figure 2. Diffusion of HIV from seminal secretions across CVM to the underlying vaginal epithelium. (A–C) Concentration profile of HIV
and broadly neutralizing antibodies (bnAb) in the semen and CVM layers at (A) T = 0 min, (B) T = 10 min, and (C) T = 30 min. (D) Flux of HIV virions
arriving at the vaginal epithelium over the first two hours post-ejaculation. 2000 virions correspond to roughly ,0.25% of the HIV viral load
(estimated by RNA copy numbers) in semen. (E) The fraction of total HIV viral load in semen that has penetrated across a 50 mm CVM layer over the
first two hours post-ejaculation.
doi:10.1371/journal.pone.0100598.g002
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Figure 3. Accumulation of different bnAb on HIV virions over time. (A) Concentration of bnAb necessary to bind to 50% of the Env spikes of
HIV (BE50) vs. in vitro IC50 measurements. Dashed line indicates that a 50% reduction in fraction of available Env trimers directly correlates to 50%
drop in overall HIV infectivity in vitro. (B) Kinetics of bnAb accumulation on HIV virions over the first two hours, as measured by the reduction in
fraction of bnAb-free vs. total Env spikes. The kon and koff values for different bnAb in Figure 3A are listed in Table 2; selected ones used in Figure 3B
are highlighted in the table.
doi:10.1371/journal.pone.0100598.g003
Figure 4. Accumulation of NIH45-46 on HIV virions that have diffused across CVM over the first two hours post-ejaculation. (A–C)
Distribution of number of NIH45-46 bound per HIV virion that penetrated CVM, where the initial NIH45-46 concentrations in CVM is (A) 0.1 mg/mL, (B)
1 mg/mL and (C) 5 mg/mL. HIV virions are assumed to have n = 1467 Env spikes; IC50 of NIH45-46 for given kon/koff pair (YU2 gp140) is ,0.050 mg/mL.
(D–F) Distribution of number of NIH45-46-free Env spikes on HIV virions that penetrated CVM, where the initial NIH45-46 concentrations in CVM is (A)
0.1 mg/mL, (B) 1 mg/mL and (C) 5 mg/mL. (G–H) Estimated initial concentration of different bnAb in CVM necessary to reduce the average number of
bnAb-free Env trimers by (G) 50% (i.e. BE50) and (H) 80% (i.e. BE80) (indicated by bars), compared to previously reported IC50 and IC80 values for the
respective bnAb (indicated by lines). Listed number in (G) and (H) above each bar represents the ratio of BE50 vs. IC50 and BE80 vs. IC80, respectively.
doi:10.1371/journal.pone.0100598.g004
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neutralization statistics IC50 and IC80 that do not correlate
precisely with measured reaction rates kon and koff, we adopt an
effective unbinding rate for koff as described in the following
section.
bnAb neutralization of HIV
Determining the number of bnAb required to neutralize a given
virion remains an active area of research, due to the difficulty in
simultaneously distinguishing the number of Ab necessary to
neutralize a particular Env spike and the minimum number of Ab-
free Env spike necessary for HIV to successfully infect [23]. It was
previously proposed that the binding of a single Ab molecule to an
Env spike is sufficient to inactivate the infectivity associated with
that spike [26]. The minimum number of Ab-free Env spikes, and
consequently the number of Env spikes that must be inactivated to
neutralize a virion, remain more controversial. Estimates for
minimum infectivity ranged from a single Ab-free Env spike [26]
to many [27,28]. For our current model, we assume that each
additional Ab binding to a previously unoccupied Env incremen-
tally reduces the likelihood of infection. To validate the hypothesis
that neutralization scales approximately with the decrease in the
number of Ab-free Env spikes, we performed a steady state
analysis of bnAb accumulation on HIV using reported binding
affinities, and compared the results to their corresponding IC50
values. When considering neutralization studies, the model
simplifies significantly because bnAb concentration is assumed to
be well-mixed and uniform u z,tð Þ: A½  for all z and t. Assuming
that each binding site interacts with the bnAb population
independently, the distribution of the number of free Env is
readily shown to be a Binomial distribution on N independent
trials with a time-dependent success probability, q tð Þ, having the
form






exp {koff 1zKA A½ ð Þt
 
:
where KA = kon=koff . Letting t??, the first term
1
1zKA A½ 
represents the steady-state probability that a given gp120 site is
free. The second term reflects that the probability of being in the
transient, initial bnAb-free state at time zero decays exponentially
with rate koff 1zKA A½ ð Þ. It follows that the fraction of Ab-free
gp120 sites in steady state is binomially distributed with 3N trials
and success probability 1zKA A½ ð Þ{1. Therefore the steady-state
probability that all three gp120 epitopes on a given Env trimeric
spike are free of bound Ab is simply 1zKA A½ ð Þ{3.
We found general agreement between IC50 values and the
predictions of this model. However, the level of agreement was not
entirely satisfactory. We believe this is because the model, by
adopting unbinding rates measured by SPR techniques in the
presence of fluid flow, likely fails to capture the rapid rebinding of
bnAb molecules that have recently become unbound, but remain
in very close proximity to the binding surface of the virion. This
leads to an overestimate of the effective unbinding rate and
consequently an underestimate of total bound bnAb. To
compensate for this gap – when attempting to emulate the
dynamics of known bnAb – we took the IC50 values as primary
indicators of bnAb performance, and developed a set of ‘‘effective
koff’’ values that calculate the kinetic rates necessary for the model
to produce the observed neutralization data.
Assuming a single bnAb bound to one of the three gp120 sites is
sufficient to render that particular Env spike non-infectious
[23,26,29], the reduction in the mean fraction of Ab-free Env
spikes on a HIV virion population is expected to correlate directly
with the drop in viral infectivity [30,31]. This enables direct
calculation of an effective koff from experimentally derived IC50







A{3. In other words, at steady state with a
concentration of bnAb equal to IC50, the combination of konand
k̂off results in 50% of the Env spikes being Ab-free. For a given
time scale T, we denote the bnAb concentrations that reduce the
average Ab-free trimers across the viral population by 50% and
80% as BE50 tð Þ and BE80 tð Þ (BE = Bound Env), respectively.
Naturally, BE50 ?ð Þ and BE80 ?ð Þ values at steady state calculated
from kon and corrected effective koff directly scale with in vitro IC50
and IC80. In virtually all cases, the corrected effective koff was
lower than experimentally measured koff (i.e., exhibiting greater
affinity to Env). Our goal in assessing how in vitro performance
compares to that in vivo essentially involves the calculation of
Figure 5. Phase diagrams correlating the kinetic constants (kon, koff) and Ab concentration necessary to achieve the desired
average reduction in the fraction of Ab-free Env spikes for HIV virions that have penetrated CVM during the first 2 hours post-
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BE50 tð Þ and BE80 tð Þ where t is the random time it takes for a
virion to traverse the CVM layer. We observe strong agreement
between these calculated BE50 2hoursð Þ values to the observed
IC50 (Figure 3A). While the introduction of an effective koff helps
bring the predictions of the kinetic model in line with in vitro
neutralization studies, we emphasize that this does not affect our
conclusion of the relative importance of kon vs. koff in vivo. This fact
is captured in the heat map representation of neutralization given
in Figure 5: changes in koff by log-decades yield only marginal
improvement in predicted in vivo protection. Indeed, this is
observed even when we remove the possibility of unbinding and
set koff to zero.
Results
HIV-1 can quickly traverse CVM layers
IgG, the predominant Ab found in CVM rather than IgA [1,2],
diffuses largely unhindered through mid-cycle human cervical
mucus [11,32]. Owing to this high diffusivity, IgG in CVM readily
enters the semen layer, and achieves essentially uniform distribu-
tion across the CVM/semen mixture within minutes (Figure 2). In
contrast, although HIV virions are readily mobile in pH-
neutralized human CVM, their effective diffusivity is over 30-fold
slower than that of IgG molecules [12]; thus, the distribution of
HIV across semen/CVM mixture remains non-uniform even after
2 hrs, with the majority of the virions (,70%) still retained in the
seminal secretions. Nevertheless, the first virions can reach the
vaginal epithelium very quickly, and it takes only ,10 and
,20 mins post-ejaculation before ,1% and ,5% of the total
HIV virions in semen (corresponding to an average of 8.46103
and 4.26104 RNA copies, assuming a median of 8.46105 RNA
copies per ejaculate) can reach the vaginal epithelium, respective-
ly. The peak HIV flux (rate of virions reaching the epithelium)
occurs roughly 20 mins post-ejaculation, and within 2 hrs nearly
30% of the initial HIV load has reached the vaginal epithelium.
These results highlight the limited time window for bnAb in CVM
to neutralize HIV virions in the vaginal lumen.
Rates of bnAb accumulation on HIV virions are slower
than generally thought
We find that many of the recently discovered bnAb require
more than 1–2 hrs to reach the steady state number of bound
bnAb per virion (Figure 3B). Even at a bnAb concentration of
1 mg/mL, which is roughly 10- to 20-fold higher than the IC50 and
IC80 for many bnAb-HIV strain pairs (with the exceptions of b12
and 2G12 against the YU-2 and HXB2 strains, respectively),
steady state virion binding is not observed for most bnAb after the
typical 1 hr incubation period. These results confirm recent data
by Ruprecht et al., which showed neutralization potencies of bnAb
steadily increase with increasing Ab-virus incubation period from
1 hr to 20 hrs [33]. Together, these results underscore the slow
binding kinetics of bnAb to HIV despite their exceptional
neutralization potencies as measured by standard pre-clinical
neutralizing antibody assays. Because our model approximates the
drop in infectivity to the decrease in the fraction rather than
absolute number of bnAb-free Env spikes, the neutralization
kinetics of different bnAb is only weakly dependent on the actual
number of Env spikes on native HIV virions.
Effective neutralization in CVM requires markedly higher
bnAb concentrations than in vitro estimates
To evaluate the competing time scales of binding and diffusion
in vivo, we combine the above virus diffusion rates and Ab-binding
kinetics to estimate the number of bound bnAb, residual Ab-free
Env proteins and relative infectivity for each HIV virion that
successfully diffuses across the CVM layer and reaches the vaginal
epithelium (Figure 4). We use NIH45-46, one of the most potent
bnAb reported to date [8] and among the fastest to achieve
equilibrium binding among the recently discovered bnAb in our
model, as the reference. The majority of viruses that reached the
vaginal epithelium have either zero or one NIH45-46 bound to
them at initial CVM concentration of 0.1 mg/mL (Figure 4A &
4D; Movie S1; IC50 = 0.05 mg/mL for YU2 strain of HIV used for
measuring affinity by SPR), suggesting NIH45-46 is unlikely to
protect against vaginal transmission of YU2 strain virions in vivo at
that particular concentration. Raising the NIH45-46 concentra-
tion in CVM to 1 mg/mL only modestly increases the number of
HIV-bound NIH45-46 (Figure 4B, 4E; Movie S2). A significant
increase in bnAb coverage, and corresponding drop in bnAb-free
Env, is only achieved at bnAb levels approaching 5 mg/mL
(Figure 4C, 4F; Movie S3). Indeed, our estimated BE50 and BE80
values for NIH45-46 against virions that penetrate CVM are 30-
and 50- fold greater than the in vitro IC50 and IC80 values (all
discussion of BE50 and BE80 values from here on refers to bnAb
concentrations necessary to reduce the fraction of Ab-free Env on
virions that penetrate CVM within 2 hrs by 50% and 80%). Much
of the decrease in mean residual Ab-free Env is observed with
virions that took relatively longer times (i.e., .30 mins) to
penetrate the CVM layer. Even at 5 mg/mL initial Ab concen-
tration in CVM, the fraction of NIH45-46-free Env sites is not
substantially reduced on virions that penetrate CVM within the
first 30 minutes post-ejaculation. Similar results are obtained even
under the extreme modeling assumption of fully suppressed Ab
unbinding; with koff = 0, the BE50 and BE80 for NIH45-46 are 1.3
and 3.8 mg/mL, respectively, which are still roughly 25- and 50-
fold greater than in vitro IC50 (0.05 mg/mL) and IC80 (0.08 mg/
mL) values. This suggests that improvement in koff alone is not
likely to improve protection in vivo.
We next estimate the bnAb accumulation kinetics for other
bnAb. For most of the recently discovered bnAb investigated with
our model, BE50 and BE80 values on virions that successfully
penetrate the CVM layer are at least 30- to 250-fold higher than
reported in vitro IC50 values. Our result is in good agreement with
studies from numerous groups that showed protection by passive
transfer of bnAb in macaques required concentrations substan-
tially greater than in vitro estimates [34–37]. The discrepancy
between the in vitro IC50 and our predicted BE50 values (or IC80 vs.
BE80) can be reduced by increasing kon (Figure 4G & 4H; Figure
S1 in File S1). Indeed, the two Ab with the highest kon in our
current analysis, 2G12 and b12, exhibit BE50 only 5-fold higher
than their IC50 estimates, despite their markedly weaker neutral-
izing potencies. Unlike many of the bnAb, 2G12 targets mannose
residues that are relatively accessible on the gp120 ‘‘glycan shield’’
[38], which likely accounts for its rapid binding kinetics. Despite
having one of the fastest unbinding rates, 2G12 has been
established as one of the most potent bnAb under in vivo conditions
[39]. For example, in a study from the Burton group [34], three
out of five macaques infused with 2G12 were completely protected
from infection, with one exhibiting delayed viral appearance and
diminished replication; in contrast, all 4 control macaques became
infected. The 90% neutralization titers (IC90) for serum 2G12 in
these animals was 1:1, suggesting 2G12 can offer substantial
protection at relatively low serum neutralizing titers [34].
The impact of kon on neutralization kinetics is insensitive
to the choice of infectivity threshold model
As discussed in the Materials and Methods section, there are a
number of infectivity models in the literature. To date, no
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experimental setup has yielded sufficient resolution to identify the
primary mechanism among these various candidates. In this
paper, we assumed infectivity scales with the fraction of Ab-free
Env. To ensure that our overall conclusions do not rest on this
assumption, we compared our results to the outcome of numerical
experiments using a minimum threshold model. In this alternate
model, in order for a virion to be infectious at all, we require that
there must be at least nmin Ab-free trimers on the virion’s surface.
The infectivity function is then incrementally increased for each




Figure S2 in File S1 shows the resulting modifications to BE50
and BE80 for the various Ab utilized in our simulations, as well as
the comparison to the respective published IC50 and IC80 values.
All BE values move closer to IC values for larger nmin, but the
large discrepancy between BE and IC values (BE50=IC50 and
BE80=IC80) is significant for all Ab other than 2G12 and b12, the
two bnAb that possess the greatest kon values in our list of bnAb-
HIV strain pairs. Furthermore, the ratio between the BE and IC
values for various Ab is similar regardless of nmin (Figure S3 in File
S1), suggesting that the choice of infectivity model does not
significantly affect the conclusions of this study.
Effectiveness of HIV neutralization in CVM is likely limited
by kon rather than koff
In the above analysis, bnAb exhibiting the lowest BE50 and
BE80 are also those with rapid kon, since these Ab can most quickly
engage an HIV virion and reduce its infectivity prior to the virion
reaching target cells. We thus seek to further analyze the antibody-
antigen affinity characteristics that would most likely effectively
neutralize HIV virions during male-to-female vaginal transmis-
sion. We find that Ab concentration and kon most directly
influence the reduction in mean number of Ab-free Env proteins
on HIV that reached the vaginal epithelium, whereas koff has a
relatively minor effect under these conditions. As long as effective
koff is less than 10
24 s21, BE80 can be achieved when the product
of kon and Ab concentration exceeds 1.3610
23 s21. Assuming that
sustainable bnAb levels elicited by vaccination are unlikely to
exceed ,1% of the total vaginal IgG levels in CVM (mean:
,5406110 mg/mL), a BE80 equivalent to this concentration must
exhibit a kon in excess of 3.5610
4 M21 s21. This kon requirement
may be reduced if higher bnAb concentrations can be achieved by
topical prophylaxis.
Discussion
Although often under-appreciated, CVM represents the first
line of defense against sexually transmitted infections in the female
reproductive tract. In addition to minimizing trauma to the
vaginal epithelium upon coital stirring, the presence of the CVM
layer also prevents virions in semen from immediately contacting
the vaginal epithelium upon ejaculation, and directly reduces the
virion flux and total viral load in semen that can reach target cells
over time. Unfortunately, since HIV is generally not slowed
substantially in CVM, there is only a very limited window of
opportunity during which secreted or topically delivered Ab can
bind to and neutralize HIV before the virion encounters target
cells. Based on published measurements of bnAb affinity to
gp120/gp140 trimers, our model predicts that many monoclonal
bnAb, at IC50 and IC80 levels measured in vitro, are likely unable to
comparably neutralize most HIV strains within the time scale of
virion diffusion through the CVM layer. Thus, despite the orders
of magnitude improvements in in vitro neutralization potencies that
extend IC50 and IC80 for many HIV strains to the ng/mL levels,
bnAb levels in excess of 5–10 mg/mL in CVM prior to coitus may
be necessary to reduce rates of transmission of diverse strains of
HIV by 50–80%, especially against the virion outliers that traverse
the CVM layer most rapidly (Figure 4G & 4H). While the failure
of bnAb-based pre-exposure prophylaxis is frequently attributed to
poor extravasation of systemic IgG into genital secretions or non-
uniform distribution of topically delivered bnAb in the vaginal
lumen, our model introduces a third mechanism – inadequate
neutralization kinetics, especially against rapidly diffusing virions –
as another potentially important challenge to ensure sterilizing
vaginal immunity against HIV.
The need for relatively high levels of bnAb in CVM is likely
attributed in part to a striking dilution effect due to rapid diffusive
mixing of the Ab in semen and CVM: effective bnAb levels in
CVM are reduced at least ,5-fold relative to native CVM levels
within minutes of ejaculation. While increasing initial bnAb levels
in CVM is the most obvious and direct approach to improve the
rates of bnAb accumulation on HIV, our model suggests another
potential tactic to enhancing vaginal immunity against HIV is to
focus on bnAb that quickly bind HIV virions, and not necessarily
just Ab with the highest affinity. A number of reports have
correlated the kinetic rates and affinity of different Ab to Env
proteins to their neutralization potency against HIV; low koff and
KD, rather than high kon, is often thought to be essential to
effective neutralization of the virions [40]. However, by assessing
the neutralization potency of Ab after an initial incubation period
of typically at least one hour with the virions prior to exposure to
target cells, these in vitro studies likely partially masked the
importance of kon to HIV neutralization in vivo. Thus, it is not
surprising that a low koff, which influences the rates with which
Ab-bound Env becomes free of Ab as well as the steady state
fraction of Ab-free Env proteins, correlated well with the most
potent Ab. Since typical in vitro screening does not distinguish Ab
molecules with rapid kon, the potential need for rapid neutraliza-
tion kinetics has received little attention amidst the current search
for monoclonal bnAb capable of neutralizing diverse HIV strains.
The potential importance of kon was previously raised in a study by
Steckbeck et al., who observed a significant correlation between
association rates but not the affinity of Ab binding to SIV/17E-CL
and SIVmac239 envelope proteins and the neutralization sensi-
tivities of the corresponding virus strains [41]. Ab association rates,
rather than dissociation rates, also appear to play a predominant
role in the neutralization of respiratory syncytial viruses (RSV),
where palivizumab variants with greater association rates
conferred greater neutralization potency [42]. Ab molecules with
rapid kon may be naturally selected during the human antibody
response to HIV, whereby somatic mutations lead to polyreactive
Ab capable of bivalent heteroligation between a high-affinity site
on the Env protein and a second low-affinity site on another
molecular structure on HIV. Due to the paucity of Env proteins on
HIV, these polyreactive Ab can associate on the HIV surface
substantially more quickly than non-polyreactive, homotypic
bivalent binding Ab typical of many bnAb. In a recent study,
nearly 75% of 134 monoclonal anti-gp140 Ab cloned from 6
patients with high titers of neutralizing Ab are polyreactive [43].
The binding affinity for different bnAb to HIV is typically
measured on gp120/gp140 trimers purified from a single strain of
HIV, such as YU2 or JRFL. These strains are generally considered
average to moderately easy to neutralize (e.g., VRC01
IC50:0.126 mg/mL for YU2, 0.031 mg/mL for JRFL) relative to
other transmitted HIV strains (geometric mean IC50 for
VRC01:0.34 mg/mL excluding strains that require .50 mg/mL
to neutralize). Thus, the bnAb binding affinities used in our model
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are likely representative or potentially even higher than actual
affinities to other HIV strains. While the in vitro neutralization
potency of bnAb against a large panel of HIV strains can be
rapidly assessed, no such capability currently exists to measure the
binding affinity for different bnAb against diverse HIV strains. We
are thus unable to evaluate the effective mucosal neutralization
potency for different bnAb against diverse HIV strains in our
current model. Nevertheless, we expect HIV strains that neutralize
in vitro more readily than YU2/JRFL will also be more readily
neutralized by the various bnAb at equal or lower CVM
concentrations. Correspondingly, HIV strains that are already
difficult to neutralize in vitro will likely require even higher bnAb
concentration in CVM before possible neutralization.
Although our results suggest that bnAb concentrations in
marked excess of in vitro IC50 and IC80 must be present in CVM to
block vaginal transmission, there is increasing evidence that
effective mucosal protection may be achieved with Ab at sub-
neutralizing doses or with non-neutralizing Ab. For example,
comparable protection was found with two IgGs that exhibited
,10- to more than 100-fold difference in neutralization potency
[34], and the vaccine regimen in the recent Thai RV144 trial
enabled ,60% protection of vaccinated subjects in Year 1 despite
inducing a poor neutralizing Ab response [44]. This conundrum
might be explained by low affinity crosslinks between IgG and
mucins that lead to polyvalent, high avidity immobilization of HIV
virions, a potential mechanism of mucosal immunity that remains
largely unexplored to date. The diffusion of IgG molecules
(diameter , 10 nm) is only slightly retarded in human mucus
(pores , 340670 nm [45]) compared to buffer, indicative of low-
affinity, transient crosslinks with the mucus gel [11]. As IgG
molecules accumulate on virions such as HIV, the array of bound
Ab may form a sufficient number of transient low-affinity bonds to
mucins at any given time to effectively trap (immobilize) the virion
in the mucus gel. As few as several Ab bound per virion may
generate sufficient affinity to mucins to markedly reduce the flux of
virions reaching target cells, thereby prolonging the time window
for more complete neutralization of fast moving HIV virions likely
responsible for infections. We have recently found IgG to mediate
effective trapping of Herpes Simplex Virus at sub-neutralizing IgG
doses [46], and we are actively investigating whether bnAb may
help trap HIV virions in mucus. Nevertheless, because the precise
dynamics with which virion-bound Ab may slow virion diffusion
are yet to be determined, we did not incorporate this potential
mechanism of vaginal immunity by bnAb in our current model.
Such trapping of HIV virions in mucus prior to their diffusion to
target cells is critically dependent upon achieving maximal virion-
bound Ab within a short time window; thus, it is likely that
mucosal Ab that efficiently leverage this protective mechanism
would also exhibit rapid kon.
The thickness of CVM directly influences the time available for
bnAb to bind to virions before the virions can penetrate CVM.
When the CVM thickness is ,50 mm, substantially greater levels
of bnAb must be present in native secretions to achieve BE50 and
BE80, whereas lower levels of bnAb are needed with greater CVM
thickness. Unfortunately, the precise thickness of the CVM layer
remains poorly understood compared to those at other mucosal
surfaces such as the lung airways and the eye, due to a series of
compounding factors. For example, the volume of genital
secretions coating the vaginal epithelium can vary substantially
throughout the menstrual cycle, with maximum volume typically
occurring during mid-cycle. Genital secretions often decrease with
age due to reduction in estrogen levels, and there may be local
heterogeneities with little to no mucus present on particular
regions of the vaginal epithelium. The volume of vaginal secretions
is also influenced by coital stimulation. While increased mucus
secretion during coitus or mid-cycle is generally thought to provide
lubrication to minimize physical trauma to the epithelial layer
(e.g., microabrasions) and consequently decreased risks of infec-
tion, it may also represent an evolutionary mechanism to enhance
the diffusional and immunological barrier against sexually
transmitted pathogens.
Clearance of semen from the female reproductive tract is not
incorporated into our current model, largely because of a lack of
literature documenting the rates and hydrodynamics of seminal
fluid clearance. Nevertheless, assuming there is no gap in the
mucus secretions coating the vagina, and that infectious virions
had not already reached the vaginal epithelium prior to
ejaculation, inducing rapid semen elimination should directly
reduce the flux of virions reaching target cells and consequently
the rate of male-to-female transmission of cell-free HIV virions. As
shown in Figure 2, the first virions are unlikely to diffuse across the
CVM until a few minutes post-ejaculation, implying a potentially
critical time window for eliminating infectious virions via semen
clearance. While this practice clearly should not replace any of the
currently available methods for protection against sexually
transmitted infections, it adds to the list of behavioral and/or
readily adoptable approaches that may reduce HIV or other
sexually transmitted infections, which includes reducing the
number of sexual partners, increasing condom use, and circum-
cision.
Our current model is a first step towards an improved
quantitative understanding of the dynamics with which HIV
establishes infection in the female reproductive tract, and serves as
a foundation to incorporate additional antibody-effector functions
(e.g., ADCC, complement). Nevertheless, many of the intricacies
revealed by our analysis, such as the physiologically relevant
timescales for Ab accumulation on virions, provide quantitative
insights into strategies to improve humoral immune responses, and
should be broadly generalizable to understanding the kinetics of
other viral infections at mucosal surfaces. We expect additional
iterations and future improvements to our model will provide
predictive insights into the Ab doses needed for ensuring protective
vaginal immunity against HIV and other sexually transmitted
infections.
Supporting Information
File S1 Supplemental methods, supporting figures, and
supporting figure legends.
(PDF)
File S2 MATLAB codes for simulation.
(ZIP)
Movie S1 Diffusion of HIV across cervicovaginal mucus
with initial NIH45-46 concentration of 0.1 mg/mL, from
0–120 mins post-ejaculation.
(AVI)
Movie S2 Diffusion of HIV across cervicovaginal mucus
with initial NIH45-46 concentration of 1 mg/mL, from 0–
120 mins post-ejaculation.
(AVI)
Movie S3 Diffusion of HIV across cervicovaginal mucus
with initial NIH45-46 concentration of 5 mg/mL, from 0–
120 mins post-ejaculation.
(AVI)
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